SG11201901999XA - Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making - Google Patents

Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Info

Publication number
SG11201901999XA
SG11201901999XA SG11201901999XA SG11201901999XA SG11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA SG 11201901999X A SG11201901999X A SG 11201901999XA
Authority
SG
Singapore
Prior art keywords
international
california
loxl2
methods
inhibitor
Prior art date
Application number
SG11201901999XA
Inventor
David Lonergan
Kevin Ross Holme
Martin W Rowbottom
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of SG11201901999XA publication Critical patent/SG11201901999XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 011101111H 1110 11111 00 11110 1111 MI Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/048943 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: (74) Agent: ZUNIC, Valentin B.; Wilson Sonsini Goodrich & C07D 401/12 (2006.01) A61K 31/4439 (2006.01) Rosati, 650 Page Mill Road, Palo Alto, California 94304 (21) International Application Number: (US). PCT/US2017/050332 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 06 September 2017 (06.09.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, F1, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/384,596 07 September 2016 (07.09.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: PHARMAKEA, INC. [US/US]; 3030 Bunker TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Hill Street, Suite 300, San Diego, California 92109 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: LONERGAN, David; 307 N Rios Ave., Solana kind of regional protection available): ARIPO (BW, GH, Beach, California 92075 (US). HOLME, Kevin Ross; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 13644 Landfair Road, San Diego, California 92130 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, ROWBOTTOM, Martin W.; 8389 Reagan Glen, San TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Diego, California 92127 (US). — EE, ES, F1, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: CRYSTALLINE FORMS OF A LYSYL = = = = = = = = _ _ = 1-1 OXIDASE-LIKE 2 INHIBITOR XRPD ./ of Ii FIGURE Compound , 1 2, Form AND 1 METHODS OF MAKING Lk) ‘, 1 c 7 9 9 10 „ 12 13 10 1„6 1„0 19 „ 21 22 23 24 25 2C 27 20 e9 en 2-Theta Scale 11' ER/M-1749-63-14 C:7 GC 7r c: : :: , (57) : Described herein are crystalline forms of pharmaceutically acceptable salts of the 1ysy1 oxidase-like 2 (LOXL2) in- -- --- GC hibitor (3-(4-(aminomethyl)-6-(trifluoromethyppyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-y1)methanone. Also ,—I described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 in- CZ hibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity. ei C [Continued on next page] WO 2018/048943 Al MIDEDIMOMOIDEIREEMOOVIVEIMOIMIDOMEHOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201901999XA 2016-09-07 2017-09-06 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making SG11201901999XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384596P 2016-09-07 2016-09-07
PCT/US2017/050332 WO2018048943A1 (en) 2016-09-07 2017-09-06 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Publications (1)

Publication Number Publication Date
SG11201901999XA true SG11201901999XA (en) 2019-04-29

Family

ID=61561660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901999XA SG11201901999XA (en) 2016-09-07 2017-09-06 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Country Status (14)

Country Link
US (2) US10774069B2 (en)
EP (1) EP3510023A4 (en)
JP (1) JP7079772B2 (en)
KR (1) KR102587178B1 (en)
CN (1) CN109983006B (en)
AU (1) AU2017324445A1 (en)
BR (1) BR112019004517A2 (en)
CA (1) CA3036064A1 (en)
EA (1) EA201990621A1 (en)
IL (1) IL265192A (en)
MA (1) MA46204A (en)
MX (1) MX2019002615A (en)
SG (1) SG11201901999XA (en)
WO (1) WO2018048943A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
EA034891B1 (en) 2015-03-06 2020-04-02 Фармакеа, Инк. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
US10588900B2 (en) 2016-02-09 2020-03-17 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
JP7097874B2 (en) 2016-09-07 2022-07-08 ファーマケア，インク． Use of lysyl oxidase-like 2 inhibitor
US10774069B2 (en) 2016-09-07 2020-09-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
EE200200400A (en) 2000-01-18 2003-10-15 Pfizer Products Inc. Corticotropin releasing factor antagonists
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (en) 2003-01-09 2003-01-09 Orion Corp New compounds
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
WO2007016784A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
JP2007519705A (en) 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Combination of atypical antipsychotics and aminomethylpyridyloxymethyl / benzisoxazole azabicyclo derivatives for the treatment of CNS disorders
ES2347577T3 (en) 2004-03-12 2010-11-02 Eli Lilly And Company OPIOID RECEPTOR ANTAGONISTS.
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
BRPI0515143A (en) 2004-09-10 2008-07-08 Pfizer Prod Inc uses of azabicyclic pyridyloxymethyl and benzisoxazole derivatives for the preparation of a pharmaceutical composition for the treatment of mood disorders
JP2008512441A (en) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク Method for treating cognitive impairment using pyridyloxymethyl and benzisoxazole azabicyclo derivatives
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (en) 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Novel inhibitors of lysyl oxidase
WO2006083781A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
AR055041A1 (en) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd TIADIAZOLS AND OXADIAZOLS AS INHIBITORS OF THE SYNTHESIS OF LEUCOTRIENOS. PHARMACEUTICAL COMPOSITIONS.
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (en) * 2005-10-14 2007-04-15 Procos Spa ANANTIOMERIC RESOLUTION PROCESS OF 2-AMINOMETHYL-PYRROLIDINES 1-SUBSTITUTED FOR DAMAGE IN THE PRESENCE OF LIPASE
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2402334T3 (en) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedures and compositions for the treatment and diagnosis of fibrosis
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
MX2012002271A (en) 2009-08-21 2012-07-20 Gilead Biologics Inc Therapeutic methods and compositions.
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
SG190839A1 (en) * 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
JP6073343B2 (en) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Substituted bicyclic azaheterocycles and analogs as sirtuin regulators
IN2014MN01982A (en) 2012-04-25 2015-07-10 Raqualia Pharma Inc
CN104755501A (en) * 2012-10-30 2015-07-01 吉联亚科学公司 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
JP6301842B2 (en) 2012-12-18 2018-03-28 Ｅａファーマ株式会社 Heterocyclic amide derivative and pharmaceutical containing the same
JP2018522812A (en) 2014-08-05 2018-08-16 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア Caspase-6 modulator
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
EA033497B1 (en) 2015-02-15 2019-10-31 Hoffmann La Roche 1-(thiophenyl or phenyl)sulfonyl(pyrrolidine)-2-carboxamide derivatives and use thereofas trpa1 antagonists
EA034891B1 (en) * 2015-03-06 2020-04-02 Фармакеа, Инк. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
US10774069B2 (en) * 2016-09-07 2020-09-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
JP7097874B2 (en) 2016-09-07 2022-07-08 ファーマケア，インク． Use of lysyl oxidase-like 2 inhibitor

Also Published As

Publication number Publication date
US20190202805A1 (en) 2019-07-04
CA3036064A1 (en) 2018-03-15
US11459309B2 (en) 2022-10-04
MX2019002615A (en) 2019-10-15
MA46204A (en) 2021-03-17
EA201990621A1 (en) 2019-09-30
AU2017324445A1 (en) 2019-04-11
BR112019004517A2 (en) 2019-08-13
US20200361901A1 (en) 2020-11-19
IL265192A (en) 2019-05-30
CN109983006A (en) 2019-07-05
JP2019532919A (en) 2019-11-14
EP3510023A4 (en) 2020-03-18
CN109983006B (en) 2022-02-25
WO2018048943A1 (en) 2018-03-15
JP7079772B2 (en) 2022-06-02
EP3510023A1 (en) 2019-07-17
KR102587178B1 (en) 2023-10-06
KR20190052040A (en) 2019-05-15
US10774069B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
SG11201901999XA (en) Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408067YA (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201408140QA (en) Crystalline forms of an androgen receptor modulator
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201906222WA (en) Jak1 selective inhibitors